About the Company
neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (il)-2/il-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. the company was formerly known as aquinox pharmaceuticals, inc. and changed its name to neoleukin therapeutics, inc. in august 2019. neoleukin therapeutics, inc. was founded in 2003 and is headquartered in seattle, washington.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $NLTX News
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the ...
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
The post 7 A-Rated Aggressive Biotech Stocks to Bet On in 2024 appeared first on InvestorPlace.
Intellia Therapeutics Inc NTLA
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
FULC Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high ...
ATXS Astria Therapeutics, Inc.
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States.
Revance Therapeutics, Inc. (RVNC)
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Cargo Therapeutics Inc CRGX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Outlook Therapeutics, Inc. (OTLK)
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of ...
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno ...
Design Therapeutics, Inc.
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small ...
Loading the latest forecasts...